Skip to main content
. Author manuscript; available in PMC: 2015 Nov 27.
Published in final edited form as: Blood Cells Mol Dis. 2010 Nov 10;46(1):95–102. doi: 10.1016/j.bcmd.2010.10.006

Table 2.

Demographic and clinical characteristics of GD1 patients with and without Parkinsonism, after matching.

Patients without
Parkinsonism
reported
Patients with
Parkinsonism
reported
p-value
Patients enrolled 649 68
Age at Gaucher diagnosisa (years) n = 598 n = 65 0.0208
  Median (25th, 75th) 29 (14, 46) 41 (19, 49)
  Mean (SD) 31 (20) 37 (20)
  Min, max 0, 85 3, 80
Age at Gaucher diagnosisa, n (%) n = 598 n = 65 0.0269
  Prenatal to <10 years 109 (18.2) 10 (15.4)
  10 to <20 years 95 (15.9) 7 (10.3)
  20 to <30 years 110 (18.4) 6 (8.8)
  30 to <40 years 89 (14.9) 8 (11.8)
  40 to <50 years 75 (12.5) 18 (26.5)
  50 to <60 years 62 (10.4) 7 (10.3)
  60 to <70 years 37 (6.2) 7 (10.3)
  70 years or more 21 (3.5) 2 (2.9)
Treatment status, n (%) n = 649 n = 68 0.0808
  Ever on imiglucerase 565 (87.1) 54 (79.4)
  Never on imiglucerase 84 (12.9) 14 (20.6)
Age at first infusion (years) n = 564 n = 54 0.0028
  Median (25th, 75th) 47 (38, 58) 54 (47, 63)
  Mean (SD) 48 (14) 54 (13)
  Min, max 9, 87 15, 80
Deceased, n (%) n = 649 n = 68 0.0573
  Yes 88 (13.6) 15 (22.1)
  No 561 (86.4) 53 (77.9)
Age at death (years) n = 83 n = 13 0.0018
  Median (25th, 75th) 62 (50, 75) 73 (71, 75)
  Mean (SD) 63 (15) 72 (8)
  Min, max 20, 89 50, 85
Ethnicity, n (%) n = 368 n = 57 0.4591
  Caucasian, non-Jewish 109 (29.6) 15 (26.3)
  Jewish, Ashkenazi 241 (65.5) 37 (64.9)
  All others 18 (4.9) 5 (8.8)
Splenectomy status, n (%) n = 649 n = 68 0.0128
  Never splenectomized 356 (54.9) 48 (70.6)
  Ever splenectomized 293 (45.1) 20 (29.4)
Age at onset of Parkinsonism (years) n = 61
  Median (25th,75th) 56 (49, 64)
  Mean (SD) 57 (10)
  Min, max 30, 80
a

Patients with no diagnosis date or with diagnosis date earlier than 1 year prior to their birth were excluded from the analysis.

HHS Vulnerability Disclosure